MedTrace Logo

A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout

NCT01736514 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2014-10-29

No results posted yet for this study

Summary

This is a multicenter, open label, randomized, allopurinol-controlled, parallel-design study. Approximately 120 subjects will be randomly assigned in 1:1 ratio to receive febuxostat, or allopurinol for subjects with gout.

Conditions

Interventions

DRUG

febuxostat

oral

DRUG

Allopurinol

oral

Sponsors & Collaborators

  • Astellas Pharma Taiwan, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Astellas Pharma Taiwan, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01736514 on ClinicalTrials.gov